Myofibroblastic CAF and Malignant Ductal Cell Crosstalk Drives Epithelial-Mesenchymal Transition and Progression in Pancreatic Ductal Adenocarcinoma via THBS2-SDC/Integrin Axes.

Zhonglu Ren, Zhuangchang Li, Jie Wang, Yuchen Liu, Lidan Chen, Yuxin Su, Limin Zhao, Xi Liu

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhonglu RenSchool of Medical Information and Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China.ORCID 0000-0001-8834-0779

Zhuangchang LiSchool of Medical Information and Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Jie WangSchool of Medical Information and Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Yuchen LiuSchool of Medical Information and Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Lidan ChenSchool of Medical Information and Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Yuxin SuSchool of Medical Information and Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Limin ZhaoSchool of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan 528458, China.

Xi LiuSchool of Medical Information and Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China.

Funding

Guangzhou Municipal Science and Technology Bureau No. 202201010764Health Commission of Guangdong Province No. B2025067Traditional Chinese Medicine Bureau of Guangdong Province No. 20231219Undergraduate Innovation and Training Program 2025 Provincial-level Project No. 45Undergraduate Innovation and Training Program 2026 National-level Project No. 202610573010

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a five-year survival rate below 10%. Cancer-associated fibroblasts (CAFs) promote epithelial-mesenchymal transition (EMT) and metastasis, yet the specific CAF subtypes and molecular axes driving PDAC progression remain incompletely understood. Here, using multi-omics data from PDAC samples, we identified a malignant ductal subpopulation, termed Ductal-T0, characterized by the highest EMT activity and prominent acquisition of myofibroblastic CAF (myCAF)-like transcriptional programs. Computationally, we predicted that myCAF-secreted

Indexed as

Cancer-Associated FibroblastsCarcinoma, Pancreatic DuctalEpithelial-Mesenchymal TransitionIntegrinsMyofibroblastsPancreatic NeoplasmsThrombospondinsCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansSignal TransductionThrombospondin 2IntegrinsThrombospondin 2Thrombospondinsepithelial–mesenchymal transitionmulti-omics analysismyCAFsPDACTHBS2-SDC/integrin axes

Identifiers

PMID42589604

DOI10.3390/ijms27156951

PMCPMC13466557

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.